Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
A Phase II, Multicenter Clinical Trial Evaluating the Use of Humanized Monoclonal Anti-CD3 Antibody Visilizumab(Nuvion) as Second-line Therapy for Glucocorticoid-Refractory, Acute Graft-Versus-Host Disease
Sponsor: Facet Biotech
Listed as NCT00032279, this PHASE2 trial focuses on Graft-vs-Host Disease and remains ongoing. Sponsored by Facet Biotech, it has been updated 7 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
May 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2021 — May 2022 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Mar 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Facet Biotech
- Fred Hutchinson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .